Statin-associated autoimmune myopathy

New England Journal of Medicine

Volumn 374, Issue 7, 2016, Pages 664-669

  Mammen, Andrew L ^a,b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; GLUCOCORTICOID; PREDNISONE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; ELECTROMYOGRAPHY; HUMAN; INCIDENCE; MUSCLE WEAKNESS; MYOPATHY; PATHOGENESIS; PHYSICAL EXAMINATION; PLASMACYTOID DENDRITIC CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATIN ASSOCIATED AUTOIMMUNE MYOPATHY; ALGORITHM; AUTOIMMUNE DISEASES; CHEMICALLY INDUCED; IMMUNOLOGY; MUSCULAR DISEASES; PATHOLOGY; SKELETAL MUSCLE;

ALGORITHMS; AUTOIMMUNE DISEASES; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PREDNISONE;

EID: 84959036898     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1515161     Document Type: Review

References (37)

1. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014;168:6-15.
2. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(8A):52C-60C.
3. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.
4. Echaniz-Laguna A, Mohr M, Tran-chant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010; 362: 564-5.
5. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200.
6. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myop-athy associated with statins. Muscle Nerve 2010;41:185-90.
7. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mam-men AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-66.
8. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A re-ductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713-21.
9. Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necro-tizing autoimmune myopathy. Neurol Neu-roimmunol Neuroinflamm 2015;2(3):e96.
10. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotiz-ing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150-7.
11. Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014;96:470-6.
12. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neu-rol 2013;26:554-60.
13. Lahaye C, Beaufrére AM, Boyer O, Drouot L, Soubrier M, Tournadre A. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins. Joint Bone Spine 2014; 81: 79-82.
14. Hamann PD, Cooper RG, McHugh NJ, Chinoy H. Statin-induced necrotizing myositis-a discrete autoimmune entity within the "statin-induced myopathy spectrum." Autoimmun Rev 2013; 12: 1177-81.
15. Padala S, Thompson PD. Statins as a possible cause of inf lammatory and nec-rotizing myopathies. Atherosclerosis 2012; 222:15-21.
16. Klein M, Mann H, Ple-tilová L, et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford) 2015; 54:2010-4.
17. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroin-flamm 2015;2:e124.
18. Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007; 154:655-61.
19. Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 2015;52:189-95.
20. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005; 288: R345-53.
21. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010;298:R1173-87.
22. Tidball JG. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol 2011;1:2029-62.
23. Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) 2015;94(4):e416.
24. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 2004;14:337-45.
25. Kassardjian CD, Lennon VA, Al-fugham NB, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015;72:996-1003.
26. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 373: 393-4.
27. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glu-taryl-coenzyme a reductase in patients with immune-mediated myositis and necrotiz-ing myopathy. Muscle Nerve 2015; 52: 196-203.
28. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglu-taryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskelet al side effects. Arthritis Care Res (Hoboken) 2012; 64: 269-72.
29. Werner JL, Christopher-Stine L, Ghaz-arian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coen-zyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64: 4087-93.
30. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1∗11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012;64:1233-7.
31. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-30.
32. Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005;12:121-31.
33. Martini C, Trapani L, Narciso L, Marino M, Trentalance A, Pallottini V. 3-Hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation. J Cell Physiol 2009; 220: 524-30.
34. Trapani L, Segatto M, La Rosa P, et al. 3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration. J Cell Biochem 2012; 113: 2057-63.
35. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced my-opathy-a genomewide study. N Engl J Med 2008;359:789-99.
36. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011;305:183-90.
37. Mammen AL, Tiniakou E. Intravenous immunoglobulin for statin-triggered autoimmune myopathy. N Engl J Med 2015; 373:1680-2.